The April 2026 final order under Acting Attorney General Todd Blanche moved FDA-approved marijuana products and state-licensed medical cannabis to Schedule III, providing immediate tax relief under Section 280E for those categories while leaving broader marijuana—including adult-use products—in Schedule I. An expedited DEA administrative hearing on full rescheduling to Schedule III ran from June 29 to July 15, 2026; the record closed after testimony, with DEA’s own post-hearing brief arguing that marijuana now meets Schedule III criteria due to accepted medical use and safety under supervision. The administrative law judge’s recommendation and DEA Administrator decision remain pending, with further litigation widely expected before any final rule takes effect. These procedural steps and potential court delays explain trader consensus favoring later or no near-term resolution on comprehensive rescheduling.
Résumé expérimental généré par IA à partir des données Polymarket. Ceci n'est pas un conseil de trading et ne joue aucun rôle dans la résolution de ce marché. · Mis à jour$812,173 Vol.
31 déc. 2026
30 septembre
2%
31 décembre
28%
$812,173 Vol.
30 septembre
$719 Vol.
2%
31 décembre
$201,883 Vol.
28%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.The April 2026 final order under Acting Attorney General Todd Blanche moved FDA-approved marijuana products and state-licensed medical cannabis to Schedule III, providing immediate tax relief under Section 280E for those categories while leaving broader marijuana—including adult-use products—in Schedule I. An expedited DEA administrative hearing on full rescheduling to Schedule III ran from June 29 to July 15, 2026; the record closed after testimony, with DEA’s own post-hearing brief arguing that marijuana now meets Schedule III criteria due to accepted medical use and safety under supervision. The administrative law judge’s recommendation and DEA Administrator decision remain pending, with further litigation widely expected before any final rule takes effect. These procedural steps and potential court delays explain trader consensus favoring later or no near-term resolution on comprehensive rescheduling.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Marché ouvert : Feb 7, 2026, 5:04 PM ET
Volume
$812,173Date de fin
1 janv. 2027Marché ouvert
Feb 7, 2026, 5:04 PM ETRésolveur
0x65070BE91...This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.The April 2026 final order under Acting Attorney General Todd Blanche moved FDA-approved marijuana products and state-licensed medical cannabis to Schedule III, providing immediate tax relief under Section 280E for those categories while leaving broader marijuana—including adult-use products—in Schedule I. An expedited DEA administrative hearing on full rescheduling to Schedule III ran from June 29 to July 15, 2026; the record closed after testimony, with DEA’s own post-hearing brief arguing that marijuana now meets Schedule III criteria due to accepted medical use and safety under supervision. The administrative law judge’s recommendation and DEA Administrator decision remain pending, with further litigation widely expected before any final rule takes effect. These procedural steps and potential court delays explain trader consensus favoring later or no near-term resolution on comprehensive rescheduling.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Volume
$812,173Date de fin
1 janv. 2027Marché ouvert
Feb 7, 2026, 5:04 PM ETRésolveur
0x65070BE91...The April 2026 final order under Acting Attorney General Todd Blanche moved FDA-approved marijuana products and state-licensed medical cannabis to Schedule III, providing immediate tax relief under Section 280E for those categories while leaving broader marijuana—including adult-use products—in Schedule I. An expedited DEA administrative hearing on full rescheduling to Schedule III ran from June 29 to July 15, 2026; the record closed after testimony, with DEA’s own post-hearing brief arguing that marijuana now meets Schedule III criteria due to accepted medical use and safety under supervision. The administrative law judge’s recommendation and DEA Administrator decision remain pending, with further litigation widely expected before any final rule takes effect. These procedural steps and potential court delays explain trader consensus favoring later or no near-term resolution on comprehensive rescheduling.
Résumé expérimental généré par IA à partir des données Polymarket. Ceci n'est pas un conseil de trading et ne joue aucun rôle dans la résolution de ce marché. · Mis à jour
Méfiez-vous des liens externes.
Méfiez-vous des liens externes.
Questions fréquentes